The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Companion Diagnostics for Oncology-Global Market Insights and Sales Trends 2025
Synopsis
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
The global Companion Diagnostics for Oncology market size is expected to reach US$ 8392.9 million by 2029, growing at a CAGR of 10.8% from 2023 to 2029. The market is mainly driven by the significant applications of Companion Diagnostics for Oncology in various end use industries. The expanding demands from the Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Laboratories and Others, are propelling Companion Diagnostics for Oncology market. Polymerase Chain Reaction (PCR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Next-Generation Sequencing (NGS) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Companion Diagnostics for Oncology, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Companion Diagnostics for Oncology market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Companion Diagnostics for Oncology market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Companion Diagnostics for Oncology sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Companion Diagnostics for Oncology covered in this report include Agilent Technologies, Illumina, Roche, BioMérieux, Foundation Medicine, ArcherDX, Qiagen, Thermo Fisher Scientific and Amoy Diagnostics, etc.
The global Companion Diagnostics for Oncology market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Agilent Technologies
Illumina
Roche
BioMérieux
Foundation Medicine
ArcherDX
Qiagen
Thermo Fisher Scientific
Amoy Diagnostics
Abbott
Global Companion Diagnostics for Oncology market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Companion Diagnostics for Oncology market, Segment by Type:
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Global Companion Diagnostics for Oncology market, by Application
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Companion Diagnostics for Oncology companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Companion diagnostic (CDx) is a diagnostic testing kit majorly used by pharmaceutical companies for the development of personalized medicine. CDx tests provide information about the effective use of a corresponding therapeutic product by analyzing the genetic material. With the rise in cancer prevalence, coupled with increasing strategic initiatives, there has been a huge demand for companion diagnostics in the oncology area.
The global Companion Diagnostics for Oncology market size is expected to reach US$ 8392.9 million by 2029, growing at a CAGR of 10.8% from 2023 to 2029. The market is mainly driven by the significant applications of Companion Diagnostics for Oncology in various end use industries. The expanding demands from the Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations, Laboratories and Others, are propelling Companion Diagnostics for Oncology market. Polymerase Chain Reaction (PCR), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Next-Generation Sequencing (NGS) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Companion Diagnostics for Oncology, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Companion Diagnostics for Oncology market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Companion Diagnostics for Oncology market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Companion Diagnostics for Oncology sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Companion Diagnostics for Oncology covered in this report include Agilent Technologies, Illumina, Roche, BioMérieux, Foundation Medicine, ArcherDX, Qiagen, Thermo Fisher Scientific and Amoy Diagnostics, etc.
The global Companion Diagnostics for Oncology market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Agilent Technologies
Illumina
Roche
BioMérieux
Foundation Medicine
ArcherDX
Qiagen
Thermo Fisher Scientific
Amoy Diagnostics
Abbott
Global Companion Diagnostics for Oncology market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Companion Diagnostics for Oncology market, Segment by Type:
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Global Companion Diagnostics for Oncology market, by Application
Pharmaceutical and Biopharmaceutical Companies
Contract Research Organizations
Laboratories
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Companion Diagnostics for Oncology companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Companion Diagnostics for Oncology
1.1 Companion Diagnostics for Oncology Market Overview
1.1.1 Companion Diagnostics for Oncology Product Scope
1.1.2 Companion Diagnostics for Oncology Market Status and Outlook
1.2 Global Companion Diagnostics for Oncology Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Companion Diagnostics for Oncology Market Size by Region (2018-2029)
1.4 Global Companion Diagnostics for Oncology Historic Market Size by Region (2018-2023)
1.5 Global Companion Diagnostics for Oncology Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Companion Diagnostics for Oncology Market Size (2018-2029)
1.6.1 North America Companion Diagnostics for Oncology Market Size (2018-2029)
1.6.2 Europe Companion Diagnostics for Oncology Market Size (2018-2029)
1.6.3 Asia-Pacific Companion Diagnostics for Oncology Market Size (2018-2029)
1.6.4 Latin America Companion Diagnostics for Oncology Market Size (2018-2029)
1.6.5 Middle East & Africa Companion Diagnostics for Oncology Market Size (2018-2029)
2 Companion Diagnostics for Oncology Market by Type
2.1 Introduction
2.1.1 Polymerase Chain Reaction (PCR)
2.1.2 Next-Generation Sequencing (NGS)
2.2 Global Companion Diagnostics for Oncology Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Companion Diagnostics for Oncology Historic Market Size by Type (2018-2023)
2.2.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Companion Diagnostics for Oncology Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Companion Diagnostics for Oncology Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Companion Diagnostics for Oncology Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Companion Diagnostics for Oncology Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Companion Diagnostics for Oncology Revenue Breakdown by Type (2018-2029)
3 Companion Diagnostics for Oncology Market Overview by Application
3.1 Introduction
3.1.1 Pharmaceutical and Biopharmaceutical Companies
3.1.2 Contract Research Organizations
3.1.3 Laboratories
3.1.4 Others
3.2 Global Companion Diagnostics for Oncology Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Companion Diagnostics for Oncology Historic Market Size by Application (2018-2023)
3.2.2 Global Companion Diagnostics for Oncology Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Companion Diagnostics for Oncology Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Companion Diagnostics for Oncology Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Companion Diagnostics for Oncology Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Companion Diagnostics for Oncology Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Companion Diagnostics for Oncology Revenue Breakdown by Application (2018-2029)
4 Companion Diagnostics for Oncology Competition Analysis by Players
4.1 Global Companion Diagnostics for Oncology Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Companion Diagnostics for Oncology as of 2022)
4.3 Date of Key Players Enter into Companion Diagnostics for Oncology Market
4.4 Global Top Players Companion Diagnostics for Oncology Headquarters and Area Served
4.5 Key Players Companion Diagnostics for Oncology Product Solution and Service
4.6 Competitive Status
4.6.1 Companion Diagnostics for Oncology Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Agilent Technologies
5.1.1 Agilent Technologies Profile
5.1.2 Agilent Technologies Main Business
5.1.3 Agilent Technologies Companion Diagnostics for Oncology Products, Services and Solutions
5.1.4 Agilent Technologies Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.1.5 Agilent Technologies Recent Developments
5.2 Illumina
5.2.1 Illumina Profile
5.2.2 Illumina Main Business
5.2.3 Illumina Companion Diagnostics for Oncology Products, Services and Solutions
5.2.4 Illumina Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.2.5 Illumina Recent Developments
5.3 Roche
5.3.1 Roche Profile
5.3.2 Roche Main Business
5.3.3 Roche Companion Diagnostics for Oncology Products, Services and Solutions
5.3.4 Roche Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.3.5 BioMérieux Recent Developments
5.4 BioMérieux
5.4.1 BioMérieux Profile
5.4.2 BioMérieux Main Business
5.4.3 BioMérieux Companion Diagnostics for Oncology Products, Services and Solutions
5.4.4 BioMérieux Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.4.5 BioMérieux Recent Developments
5.5 Foundation Medicine
5.5.1 Foundation Medicine Profile
5.5.2 Foundation Medicine Main Business
5.5.3 Foundation Medicine Companion Diagnostics for Oncology Products, Services and Solutions
5.5.4 Foundation Medicine Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.5.5 Foundation Medicine Recent Developments
5.6 ArcherDX
5.6.1 ArcherDX Profile
5.6.2 ArcherDX Main Business
5.6.3 ArcherDX Companion Diagnostics for Oncology Products, Services and Solutions
5.6.4 ArcherDX Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.6.5 ArcherDX Recent Developments
5.7 Qiagen
5.7.1 Qiagen Profile
5.7.2 Qiagen Main Business
5.7.3 Qiagen Companion Diagnostics for Oncology Products, Services and Solutions
5.7.4 Qiagen Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.7.5 Qiagen Recent Developments
5.8 Thermo Fisher Scientific
5.8.1 Thermo Fisher Scientific Profile
5.8.2 Thermo Fisher Scientific Main Business
5.8.3 Thermo Fisher Scientific Companion Diagnostics for Oncology Products, Services and Solutions
5.8.4 Thermo Fisher Scientific Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.8.5 Thermo Fisher Scientific Recent Developments
5.9 Amoy Diagnostics
5.9.1 Amoy Diagnostics Profile
5.9.2 Amoy Diagnostics Main Business
5.9.3 Amoy Diagnostics Companion Diagnostics for Oncology Products, Services and Solutions
5.9.4 Amoy Diagnostics Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.9.5 Amoy Diagnostics Recent Developments
5.10 Abbott
5.10.1 Abbott Profile
5.10.2 Abbott Main Business
5.10.3 Abbott Companion Diagnostics for Oncology Products, Services and Solutions
5.10.4 Abbott Companion Diagnostics for Oncology Revenue (US$ Million) & (2018-2023)
5.10.5 Abbott Recent Developments
6 North America
6.1 North America Companion Diagnostics for Oncology Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Companion Diagnostics for Oncology Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Companion Diagnostics for Oncology Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Companion Diagnostics for Oncology Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Companion Diagnostics for Oncology Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Companion Diagnostics for Oncology Market Dynamics
11.1 Companion Diagnostics for Oncology Industry Trends
11.2 Companion Diagnostics for Oncology Market Drivers
11.3 Companion Diagnostics for Oncology Market Challenges
11.4 Companion Diagnostics for Oncology Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
